Key terms
About TNXP
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TNXP news
Mar 11
8:23am ET
Tonix Pharma’s Tonmya Shows Promise in Fibromyalgia Study
Mar 11
8:08am ET
Tonix Pharmaceuticals presents additional efficacy data from RESILIENT
Mar 07
8:23am ET
Tonix Pharma’s TNX-102 SL Shows Promise for PTSD Treatment
Mar 07
8:18am ET
Tonix Pharmaceuticals announces publication on TNX-102 SL
Mar 06
8:22am ET
Tonix Pharma: Anticipating Tonmya’s Impact on Fibromyalgia Treatment
Mar 06
8:12am ET
Tonix Pharmaceuticals selectes EVERSANA to support launch strategy of Tonmya
Mar 05
8:22am ET
Tonix announces translation of preclinical PK parameters of TNX-1500
Mar 05
8:22am ET
Tonix Pharma Advances with Promising TNX-1500 Studies
Feb 28
8:23am ET
Tonix Pharma Advances TNX-1500 Trial, Cautions Investors
Feb 28
8:04am ET
Tonix Pharmaceuticals completes clinical stage of Phase 1 trial for TNX-1500
Feb 27
8:22am ET
Tonix Pharma Expands Asian Market Reach with Tonmya™ Study
Feb 27
8:18am ET
Tonix Pharmaceuticals announces results from clinical PK study of Tonmya
Feb 15
5:12pm ET
Tonix Pharma Shareholders Approve Strategic Financing Moves
Feb 15
11:05am ET
Biotech Alert: Searches spiking for these stocks today
Feb 14
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Feb 14
8:24am ET
Tonix Pharmaceuticals hosted KOL webinar on Phase 3 fibromyalgia trial
Feb 13
8:22am ET
Tonix Pharma Advances Tonmya™ with New FDA Application Partner
Feb 12
8:19am ET
Tonix Pharma Receives FDA Nod, Updates Investor Presentation
Feb 12
8:04am ET
Tonix Pharmaceuticals announces FDA IND clearance for trial of TNX-102 SL
Jan 31
7:08am ET
Tonix Pharmaceuticals announces research on pre-existing pain conditions, COVID
Jan 26
4:28am ET
Tonix Pharma Shareholders Approve Expansion of Shares
Jan 26
4:27am ET
Tonix Pharma Expands Authorized Stock Capacity
Jan 09
7:08am ET
Tonix Pharmaceuticals presents additional data from TNX-203 SL
Dec 22
1:59pm ET
Tonix Pharmaceuticals price target lowered to $6 from $8 at Alliance Global
Dec 20
10:35am ET
Tonix Pharmaceuticals reports Phase 3 RESILIENT study met primary endpoint
Dec 20
9:04am ET
Tonix Pharmaceuticals trading halted, news pending
No recent news articles are available for TNXP
No recent press releases are available for TNXP
TNXP Financials
Key terms
Ad Feedback
TNXP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TNXP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range